GBM harboring MET amplification or HGF autocrine activation are sensitive to MET inhibitors in preclinical models [82, 83], recent clinical trials further showed that a combination of MET and VEGF inhibitors (ontarzucimab plus bevacizumab vs. placebo plus bevacizumab) significantly improved progression free survival (PFS) and overall survival (OS) in the mesenchymal subtype of recurrent GBM patients with high tumor HGF expression [84]. This evidence concerns the gene MET and glioblastoma.